PSORS13
MCID: PSR018
MIFTS: 40

Psoriasis 13 (PSORS13)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriasis 13

MalaCards integrated aliases for Psoriasis 13:

Name: Psoriasis 13 57 12 72 15
Psoriasis Susceptibility 13 57 29 13 6
Psors13 57 12 72
Psoriasis Vulgaris 72 70
Psoriasis 72 70
Psoriasis, Susceptibility to, Type 13 39
Psoriasis 13, Susceptibility to 57
Pv 72

Classifications:



External Ids:

Disease Ontology 12 DOID:0111287
OMIM® 57 614070
OMIM Phenotypic Series 57 PS177900
MeSH 44 D011565
MedGen 41 C3279754
UMLS 70 C0033860 C0263361

Summaries for Psoriasis 13

UniProtKB/Swiss-Prot : 72 Psoriasis 13: A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

MalaCards based summary : Psoriasis 13, also known as psoriasis susceptibility 13, is related to candidiasis and discoid lupus erythematosus, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis 13 is TRAF3IP2 (TRAF3 Interacting Protein 2). The drugs Metformin and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and endothelial.

Disease Ontology : 12 A psoriasis that has material basis in variation in TRAF3IP2 on chromosome 6q21.

More information from OMIM: 614070 PS177900

Related Diseases for Psoriasis 13

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis 13 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1246)
# Related Disease Score Top Affiliating Genes
1 candidiasis 30.3 TRAF3IP2-AS1 TRAF3IP2
2 discoid lupus erythematosus 29.8 TRAF3IP2-AS1 TRAF3IP2
3 chronic mucocutaneous candidiasis 29.2 TRAF3IP2-AS1 TRAF3IP2
4 psoriasis 14, pustular 11.9
5 psoriatic arthritis 11.7
6 psoriasis 1 11.7
7 pustular psoriasis 11.7
8 guttate psoriasis 11.6
9 psoriasis 2 11.5
10 psoriasis 7 11.5
11 psoriasis 11 11.5
12 psoriasis 15, pustular 11.4
13 pustulosis palmaris et plantaris 11.4
14 psoriasis 4 11.4
15 psoriasis 3 11.4
16 psoriasis 6 11.4
17 psoriasis 10 11.4
18 psoriasis 5 11.4
19 psoriasis 12 11.4
20 psoriasis 8 11.4
21 psoriasis 9 11.4
22 psoriatic juvenile idiopathic arthritis 11.4
23 psoriasis 15 11.3
24 tranebjaerg svejgaard syndrome 11.2
25 skin disease 11.2
26 arthritis 11.2
27 juvenile rheumatoid arthritis 11.1
28 mental retardation and psoriasis 11.1
29 impetigo herpetiformis 11.1
30 geographic tongue 11.0
31 spondyloarthropathy 1 11.0
32 vitiligo-associated multiple autoimmune disease susceptibility 1 11.0
33 parapsoriasis 11.0
34 singleton-merten syndrome 1 11.0
35 rheumatoid factor-negative juvenile idiopathic arthritis 11.0
36 systemic onset juvenile idiopathic arthritis 11.0
37 dermatitis 10.9
38 dermatitis, atopic 10.9
39 subacute cutaneous lupus erythematosus 10.9
40 singleton-merten syndrome 10.8
41 temporomandibular ankylosis 10.8
42 nail disorder, nonsyndromic congenital, 1 10.8
43 combined cellular and humoral immune defects with granulomas 10.8
44 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.8
45 singleton-merten syndrome 2 10.8
46 primary cutaneous amyloidosis 10.8
47 autoimmune disease 10.7
48 arthropathy 10.7
49 inflammatory spondylopathy 10.6
50 skin carcinoma 10.6

Graphical network of the top 20 diseases related to Psoriasis 13:



Diseases related to Psoriasis 13

Symptoms & Phenotypes for Psoriasis 13

Clinical features from OMIM®:

614070 (Updated 05-Apr-2021)

UMLS symptoms related to Psoriasis 13:


pruritus; exanthema; psoriasiform rash

Drugs & Therapeutics for Psoriasis 13

Drugs for Psoriasis 13 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 4091 14219
2
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
3
Desonide Approved, Investigational Phase 4 638-94-8 5311066
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
6
Sodium citrate Approved, Investigational Phase 4 68-04-2
7
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
9
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
10
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
11
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
12
Desoximetasone Approved Phase 4 382-67-2 5311067
13
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5311052 5282493
14
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
15
Zinc Approved, Investigational Phase 4 7440-66-6 32051
16
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
17
Ustekinumab Approved, Investigational Phase 4 815610-63-0
18
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
21
Vedolizumab Approved Phase 4 943609-66-3
22
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
23
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
24
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
25
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
26
Capsaicin Approved Phase 4 404-86-4 1548943
27
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
29
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
30
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
31
Trichostatin A Experimental Phase 4 58880-19-6
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
33 Citrate Phase 4
34 Anticoagulants Phase 4
35 diuretics Phase 4
36 Chelating Agents Phase 4
37 Hydrocortisone hemisuccinate Phase 4
38 Hydrocortisone 17-butyrate 21-propionate Phase 4
39 Vitamin B9 Phase 4
40 Folic Acid Antagonists Phase 4
41 Vitamin B Complex Phase 4
42 Folate Phase 4
43 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
44 Myeloma Proteins Phase 4
45 Paraproteins Phase 4
46 Hydrocortisone-17-butyrate Phase 4
47 Bronchodilator Agents Phase 4
48 Anti-Allergic Agents Phase 4
49 Tin Fluorides Phase 4
50 Clocortolone pivalate Phase 4

Interventional clinical trials:

(show top 50) (show all 1488)
# Name Status NCT ID Phase Drugs
1 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
2 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
3 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
4 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
5 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
6 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
7 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
8 Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism: A Double-Blind, Randomized, Placebo-Controlled Study Unknown status NCT03629639 Phase 4 Metformin
9 A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis Unknown status NCT03408756 Phase 4 methotrexate
10 Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis Unknown status NCT02829424 Phase 4 Methotrexate;Methotrexate Placebo
11 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
12 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
13 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
14 A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis Unknown status NCT03553433 Phase 4 Apremilast 30mg;Placebo Oral Tablet
15 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
16 An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab Unknown status NCT03827876 Phase 4 Enstilar 0.005%-0.064% Topical Foam
17 A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis Unknown status NCT03587194 Phase 4 Otezla
18 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
19 Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis Unknown status NCT03453190 Phase 4
20 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
21 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
22 Studying the Effect of Methotrexate Alone Versus Methotrexate and Vitamin D on the Cardiovascular Risk of Psoriatic Patients Unknown status NCT03904680 Phase 4 Methotrexate;Vitamin D
23 Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis Completed NCT03348462 Phase 4 ethosomal preparation of anthralin;liposomal preparation of anthralin
24 Can an App Supporting Psoriasis Patients Improve Adherence to Topical Treatment? A Single-blind Randomized Controlled Trial Completed NCT02858713 Phase 4 Calcipotriene + Betamethasone Dipropionate
25 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
26 Energy-restricted, n-3 Polysaturated Fatty Acids-rich Diet Improves the Clinical Response to Immuno-modulating Drugs in Obese Patients With Plaque-type Psoriasis: a Randomized Control Clinical Trial. Completed NCT01876875 Phase 4
27 A Preliminary, Open Label, Single-arm Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy Completed NCT01761019 Phase 4 Taclonex Topical Suspension
28 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Completed NCT01181570 Phase 4 Adalimumab;Placebo
29 Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab Completed NCT00967538 Phase 4 etanercept 50 mg
30 An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept Completed NCT00493324 Phase 4 alefacept;polyvalent pneumococcal vaccine
31 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore Changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment With Secukinumab, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis Completed NCT03055494 Phase 4
32 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
33 A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis Completed NCT00110981 Phase 4 Etanerept;Etanercept
34 An Investigator-Initiated, Assessor Blinded, Randomized Study Comparing the Mechanism of Action of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis. Completed NCT00932113 Phase 4 Methotrexate;Adalimumab (Humira)
35 An Open Label, Prospective Cohort Pilot Study to Evaluate the Efficacy and Safety of Etanercept in the Treatment of Moderate to Severe Plaque Psoriasis in Patients Who Have Not Had an Adequate Response to Adalimumab Completed NCT00833729 Phase 4 etanercept
36 Pilot Study on the Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis Completed NCT00940862 Phase 4
37 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completed NCT02690701 Phase 4 Secukinumab 300 mg
38 A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color Completed NCT03506477 Phase 4 Enstilar® foam;Vehicle foam
39 A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Completed NCT03331835 Phase 4 Fumaric acid esters
40 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
41 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
42 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
43 Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris Completed NCT00216892 Phase 4 Calcipotriol, (calcipotriol + betamethasone)
44 A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris Completed NCT00640393 Phase 4 Etanercept
45 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed NCT01707043 Phase 4 Taclonex
46 Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris Completed NCT02004574 Phase 4 Calcipotriol/betamethasone dipropionate gel
47 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
48 A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis Completed NCT02125279 Phase 4 Calcitriol
49 A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Completed NCT03942042 Phase 4 Ixekizumab
50 Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept

Search NIH Clinical Center for Psoriasis 13

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen

Genetic Tests for Psoriasis 13

Genetic tests related to Psoriasis 13:

# Genetic test Affiliating Genes
1 Psoriasis Susceptibility 13 29 TRAF3IP2

Anatomical Context for Psoriasis 13

MalaCards organs/tissues related to Psoriasis 13:

40
Skin, Liver, Endothelial, T Cells, Bone, Pituitary, Monocytes

Publications for Psoriasis 13

Articles related to Psoriasis 13:

(show all 18)
# Title Authors PMID Year
1
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. 57 6
20953188 2010
2
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. 6 57
20953186 2010
3
An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. 6
24120361 2013
4
CIKS/Act1-mediated signaling by IL-17 cytokines in context: implications for how a CIKS gene variant may predispose to psoriasis. 6
22581863 2012
5
Comparison of p53 immunohistochemical staining in differentiated vulvar intraepithelial neoplasia (dVIN) with that in inflammatory dermatoses and benign squamous lesions in the vulva. 61
32799363 2021
6
[Pruritus in Germany-a Google search engine analysis]. 61
29876613 2019
7
Juvenile psoriasis: an epidemiological study of 69 cases. 61
27374182 2018
8
Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. 61
30214261 2018
9
Remission of psoriasis 13 years after autologous stem cell transplant. 61
26125223 2015
10
Increased subclinical atherosclerosis in patients with chronic plaque psoriasis. 61
25463081 2014
11
Severely photosensitive psoriasis: a phenotypically defined patient subset. 61
19536141 2009
12
[The anti-tubercular drugs in the treatment of psoriasis]. 61
19801725 2009
13
An exploratory population-based case-control study of primary biliary cirrhosis. 61
10796879 2000
14
Narrowband UVB phototherapy for psoriasis: results with fixed increments by skin type (as opposed to percentage increments). 61
10321520 1999
15
The chemotactic activity of T-lymphocytes in response to interleukin 8 is significantly decreased in patients with psoriasis and atopic dermatitis. 61
9028795 1996
16
[Psoriasis: development and fatal complications]. 61
2048897 1991
17
[Comparative study between 120 mg. of anapsos and a placebo in 37 psoriasis patients]. 61
6759814 1982
18
Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study. 61
781848 1976

Variations for Psoriasis 13

ClinVar genetic disease variations for Psoriasis 13:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TRAF3IP2 , TRAF3IP2-AS1 NM_147686.4(TRAF3IP2):c.28G>A (p.Asp10Asn) SNV risk factor 30630 rs33980500 GRCh37: 6:111913262-111913262
GRCh38: 6:111592059-111592059

UniProtKB/Swiss-Prot genetic disease variations for Psoriasis 13:

72
# Symbol AA change Variation ID SNP ID
1 TRAF3IP2 p.Asp19Asn VAR_047349 rs33980500

Expression for Psoriasis 13

Search GEO for disease gene expression data for Psoriasis 13.

Pathways for Psoriasis 13

GO Terms for Psoriasis 13

Sources for Psoriasis 13

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....